Stanley Lemon (University of Texas at Galveston, USA) for the HJ3-5 HCVcc clone. We thank Prof. Nadir Arber (Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, Israel) for the AdEasy plasmid system used for generation of recombinant human type 5 adenoviral vectors. References 1. Pawlotsky JM (2011) Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 53: 1742–1751. 2. Moradpour D, Penin F, Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5: 453–463. 3. Suzuki T, Ishii K, Aizaki H, Wakita T (2007) Hepatitis C viral life cycle. Adv Drug Deliv Rev. 4. De Francesco R, Carfi A (2007) Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA- dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev 59: 1242–1262. 5. Bartenschlager R (1999) The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J Viral Hepat 6: 165–181. 6. Neurath H, Walsh KA (1976) Role of proteolytic enzymes in biological regulation (a review). Proc Natl Acad Sci U S A 73: 3825–3832. 7. Richter C, Tanaka T, Yada RY (1998) Mechanism of activation of the gastric aspartic proteinases: pepsinogen, progastricsin and prochymosin. Biochem J 335(Pt 3): 481–490. 8. Donepudi M, Grutter MG (2002) Structure and zymogen activation of caspases. Biophys Chem 101–102: 145–153. 9. Davie EW (2003) A brief historical review of the waterfall/cascade of blood coagulation. J Biol Chem 278: 50819–50832. 10. Shapira A, Gal-Tanamy M, Nahary L, Litvak-Greenfeld D, Zemel R, et al. (2011) Engineered toxins ‘‘zymoxins’’ are activated by the HCV NS3 protease by removal of an inhibitory protein domain. PLoS One 6: e15916. 11. Gerdes K, Moller-Jensen J, Ebersbach G, Kruse T, Nordstrom K (2004) Bacterial mitotic machineries. Cell 116: 359–366. 12. Couturier M, Bahassi el M, Van Melderen L (1998) Bacterial death by DNA gyrase poisoning. Trends Microbiol 6: 269–275. 13. Engelberg-Kulka H, Glaser G (1999) Addiction modules and programmed cell death and antideath in bacterial cultures. Annu Rev Microbiol 53: 43–70. 14. Gerdes K, Christensen SK, Lobner-Olesen A (2005) Prokaryotic toxin-antitoxin stress response loci. Nat Rev Microbiol 3: 371–382. 15. Hayes F (2003) Toxins-antitoxins: plasmid maintenance, programmed cell death, and cell cycle arrest. Science 301: 1496–1499. 16. Yarmolinsky MB (1995) Programmed cell death in bacterial populations. Science 267: 836–837. 17. Magnuson RD (2007) Hypothetical functions of toxin-antitoxin systems. J Bacteriol 189: 6089–6092. 18. Mittenhuber G (1999) Occurrence of mazEF-like antitoxin/toxin systems in bacteria. J Mol Microbiol Biotechnol 1: 295–302. 19. Pandey DP, Gerdes K (2005) Toxin-antitoxin loci are highly abundant in free- living but lost from host-associated prokaryotes. Nucleic Acids Res 33: 966–976. 20. Van Melderen L, Saavedra De Bast M (2009) Bacterial toxin-antitoxin systems: more than selfish entities? PLoS Genet 5: e1000437. 21. Engelberg-Kulka H, Hazan R, Amitai S (2005) mazEF: a chromosomal toxin- antitoxin module that triggers programmed cell death in bacteria. J Cell Sci 118: 4327–4332. 22. Yamaguchi Y, Inouye M (2009) mRNA interferases, sequence-specific endoribonucleases from the toxin-antitoxin systems. Prog Mol Biol Transl Sci 85: 467–500. 23. Engelberg-Kulka H, Amitai S, Kolodkin-Gal I, Hazan R (2006) Bacterial programmed cell death and multicellular behavior in bacteria. PLoS Genet 2: e135. 24. Kamada K, Hanaoka F, Burley SK (2003) Crystal structure of the MazE/MazF complex: molecular bases of antidote-toxin recognition. Mol Cell 11: 875–884. 25. Li GY, Zhang Y, Chan MC, Mal TK, Hoeflich KP, et al. (2006) Characterization of dual substrate binding sites in the homodimeric structure of Escherichia coli mRNA interferase MazF. J Mol Biol 357: 139–150. 26. Inouye M (2006) The discovery of mRNA interferases: implication in bacterial physiology and application to biotechnology. J Cell Physiol 209: 670–676. 27. Shimazu T, Degenhardt K, Nur EKA, Zhang J, Yoshida T, et al. (2007) NBK/ BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition. Genes Dev 21: 929–941. 28. Anderie I, Schulz I, Schmid A (2007) Characterization of the C-terminal ER membrane anchor of PTP1B. Exp Cell Res 313: 3189–3197. 29. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, et al. (2004) Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 22: 1567–1572. 30. Wolk B, Sansonno D, Krausslich HG, Dammacco F, Rice CM, et al. (2000) Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline- regulated cell lines. J Virol 74: 2293–2304. 31. Moradpour D, Gosert R, Egger D, Penin F, Blum HE, et al. (2003) Membrane association of hepatitis C virus nonstructural proteins and identification of the Zymoxin-Mediated Removal of HCV Infected Cells Author Contributions Conceived and designed the experiments: AS SS MGT RZ RTK IB. Performed the experiments: AS SS MGT. Analyzed the data: AS SS MGT RZ RTK IB. Wrote the paper: AS MGT RZ RTK IB. membrane alteration that harbors the viral replication complex. Antiviral Res 60: 103–109. 32. Brass V, Berke JM, Montserret R, Blum HE, Penin F, et al. (2008) Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc Natl Acad Sci U S A 105: 14545–14550. 33. Egger D, Wolk B, Gosert R, Bianchi L, Blum HE, et al. (2002) Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 76: 5974–5984. 34. Wolk B, Buchele B, Moradpour D, Rice CM (2008) A dynamic view of hepatitis C virus replication complexes. J Virol 82: 10519–10531. 35. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, et al. (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95: 2509–2514. 36. Zheng C, Goldsmith CM, O’Connell BC, Baum BJ (2000) Adenoviral vector cytotoxicity depends in part on the transgene encoded. Biochem Biophys Res Commun 274: 767–771. 37. Wersto RP, Rosenthal ER, Seth PK, Eissa NT, Donahue RE (1998) Recombinant, replication-defective adenovirus gene transfer vectors induce cell cycle dysregulation and inappropriate expression of cyclin proteins. J Virol 72: 9491–9502. 38. Teramoto S, Johnson LG, Huang W, Leigh MW, Boucher RC (1995) Effect of adenoviral vector infection on cell proliferation in cultured primary human airway epithelial cells. Hum Gene Ther 6: 1045–1053. 39. Teramoto S, Matsuse T, Matsui H, Ohga E, Ishii T, et al. (1999) Recombinant E1-deleted adenovirus vector induces apoptosis in two lung cancer cell lines. Eur Respir J 13: 1125–1132. 40. Yi M, Ma Y, Yates J, Lemon SM (2007) Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J Virol 81: 629–638. 41. Bartenschlager R, Sparacio S (2007) Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res 127: 195–207. 42. Tellinghuisen TL, Evans MJ, von Hahn T, You S, Rice CM (2007) Studying hepatitis C virus: making the best of a bad virus. J Virol 81: 8853–8867. 43. Thompson AJ, McHutchison JG (2009) Review article: investigational agents for chronic hepatitis C. Aliment Pharmacol Ther 29: 689–705. 44. Greene WC, Debyser Z, Ikeda Y, Freed EO, Stephens E, et al. (2008) Novel targets for HIV therapy. Antiviral Res 80: 251–265. 45. Wainberg MA (2009) Perspectives on antiviral drug development. Antiviral Res 81: 1–5. 46. Hsu JT, Wang HC, Chen GW, Shih SR (2006) Antiviral drug discovery targeting to viral proteases. Curr Pharm Des 12: 1301–1314. 47. Patick AK, Potts KE (1998) Protease inhibitors as antiviral agents. Clin Microbiol Rev 11: 614–627. 48. Gal-Tanamy M, Zemel R, Bachmatov L, Jangra RK, Shapira A, et al. (2010) Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies. Antiviral Res 88: 95–106. 49. Trahtenherts A, Gal-Tanamy M, Zemel R, Bachmatov L, Loewenstein S, et al. (2008) Inhibition of hepatitis C virus RNA replicons by peptide aptamers. Antiviral Res 77: 195–205. 50. Gal-Tanamy M, Zemel R, Berdichevsky Y, Bachmatov L, Tur-Kaspa R, et al. (2005) HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen. J Mol Biol 347: 991–1003. 51. Varshavsky A (1995) The N-end rule. Cold Spring Harb Symp Quant Biol 60: 461–478. 52. Falnes PO, Welker R, Krausslich HG, Olsnes S (1999) Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N- end-rule pathway. Biochem J 343 Pt 1: 199–207. 53. Johnson RJ, Lin SR, Raines RT (2006) A ribonuclease zymogen activated by the NS3 protease of the hepatitis C virus. Febs J 273: 5457–5465. 54. Plainkum P, Fuchs SM, Wiyakrutta S, Raines RT (2003) Creation of a zymogen. Nat Struct Biol 10: 115–119. 55. Turcotte RF, Raines RT (2008) Design and Characterization of an HIV-Specific Ribonuclease Zymogen. AIDS Res Hum Retroviruses. 56. Jucovic M, Walters FS, Warren GW, Palekar NV, Chen JS (2008) From enzyme to zymogen: engineering Vip2, an ADP-ribosyltransferase from Bacillus cereus, for conditional toxicity. Protein Eng Des Sel 21: 631–638. 57. Law SK, Wang RR, Mak AN, Wong KB, Zheng YT, et al. (2010) A switch-on mechanism to activate maize ribosome-inactivating protein for targeting HIV- infected cells. Nucleic Acids Res. 58. Hsu EC, Hsi B, Hirota-Tsuchihara M, Ruland J, Iorio C, et al. (2003) Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers. Nat Biotechnol 21: 519–525. 59. Willis A, Jung EJ, Wakefield T, Chen X (2004) Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23: 2330–2338. PLoS ONE | www.plosone.org 16 February 2012 | Volume 7 | Issue 2 | e32320